Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product ...

Glaukos GKOS witnessed strong momentum in the year-to-date period. Shares of the company rallied 40.4% compared with 5.2% growth of the industry. The S&P 500 Composite has risen 11% during the same ...

Glaukos Corporation GKOS reported first-quarter 2024 adjusted loss of 70 cents per share, which is 20.7% wider than the Zacks Consensus Estimate of a loss of 58 cents. The figure was also wider ...

GKOS stock price gains are being driven by strong top-line growth, but profitability trends continue to disappoint. A trailing stop-loss on existing positions is the best strategy here.

Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst Glaukos reports Q1 adjusted EPS loss, sales beat estimates. Strong guidance for 2024 with positive ...